Marker Therapeutics, Inc. (MRKR) |
|
0.3294 0.015 (4.9%)
|
05-16 01:33 |
|
Open: |
0.32 |
Pre. Close: |
0.314 |
|
High:
|
0.3303 |
Low:
|
0.31 |
|
Volume:
|
524,013 |
Market Cap:
|
27(M) |
|
|
|
|
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.33 - 0.33 |
0.33 - 0.33 |
|
Low:
|
0.31 - 0.31 |
0.31 - 0.31 |
|
Close:
|
0.33 - 0.33 |
0.33 - 0.33 |
|
Technical analysis |
as of: 2022-05-13 4:39:56 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 0.43 One year: 0.5 |
| Support: |
Support1: 0.28 Support2: 0.23 |
| Resistance: |
Resistance1: 0.37 Resistance2: 0.43 |
| Pivot: |
0.33  |
| Moving Average: |
MA(5): 0.32 MA(20): 0.34
MA(100): 0.54 MA(250): 1.41 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 30.3 %D(3): 25.9 |
| RSI: |
RSI(14): 43.5 |
| 52-week: |
High: 3.65 Low: 0.28 |
| Average Vol(K): |
3-Month: 471 (K) 10-Days: 285 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ MRKR ] has closed above bottom band by 37.5%. Bollinger Bands are 66.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 18 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Thu, 12 May 2022
Marker Therapeutics, Inc. (NASDAQ:MRKR) Expected to Announce Earnings of -$0.13 Per Share - Defense World
Tue, 03 May 2022
Marker Therapeutics, Inc. (NASDAQ:MRKR) Sees Large Increase in Short Interest - Defense World
Tue, 26 Apr 2022
2022-04-26 | NDAQ:MRKR | Press Release | Marker Therapeutics Inc. - Stockhouse
Mon, 25 Apr 2022
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday - InvestorPlace
Fri, 15 Apr 2022
Short Interest in Marker Therapeutics, Inc. (NASDAQ:MRKR) Drops By 42.1% - Defense World
Thu, 17 Mar 2022
Marker Therapeutics Reports Fiscal Year 2021 Operating and Financial Results - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
83 (M) |
| Shares Float |
60 (M) |
|
% Held by Insiders
|
19.9 (%) |
|
% Held by Institutions
|
34 (%) |
|
Shares Short
|
969 (K) |
|
Shares Short P.Month
|
1,130 (K) |
Stock Financials |
|
EPS
|
-0.6 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0.62 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-39.7 |
|
Return on Equity (ttm)
|
-98.1 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
-0.23 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-0.44 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-27 (M) |
|
Levered Free Cash Flow
|
-21 (M) |
Stock Valuations |
|
PE Ratio
|
-0.56 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.52 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-1.03 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2016-09-15 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
